Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship

Recludix Pharma wants to squash the harmful effects that have plagued some JAK inhibitors and caused the FDA to tamper future hopes for the drug class by going after JAK's partner: STAT.  The new biotech snagged $60 million for its attempt to create STAT inhibitor drugs to treat cancers and inflammatory diseases.